Stockscreener 앱 받기
2.55
29.85%
-1.085
시간 외 거래:
2.53
-0.02
-0.78%
전일 마감가:
$3.635
열려 있는:
$3
하루 거래량:
1.96M
Relative Volume:
12.19
시가총액:
$34.60M
수익:
-
순이익/손실:
$-11.73M
주가수익비율:
-1.8444
EPS:
-1.3826
순현금흐름:
$-10.37M
1주 성능:
-65.02%
1개월 성능:
-36.41%
6개월 성능:
-5.41%
1년 성능:
+0.00%
1일 변동 폭
$2.34
$3.04
1주일 범위
$2.34
$7.73
52주 변동 폭
$1.80
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
명칭
Medicus Pharma Ltd
전화
610-540-7515
주소
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
MDCX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
2.55 | 98.38M | 0 | -11.73M | -10.37M | -1.3826 |
|
LLY
Lilly Eli Co
|
737.67 | 640.72B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.21 | 367.98B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
186.11 | 323.71B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.76 | 222.69B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.50 | 299.26B | 43.59B | 15.04B | 10.74B | 3.3766 |
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma prices $7 million share offering - MSN
Health Sector Experiences Mixed Fortunes As Trials And Stock Moves Shake Up Market - Finimize
Biotech Stocks Plummet As Public Offerings Shake Market - Finimize
Sector Update: Health Care - marketscreener.com
Form 424B4 Medicus Pharma Ltd. - StreetInsider
Small cap wrap: ReconAfrica, Charbone Hydrogen, Medicus Pharma.... - Proactive financial news
Medicus Pharma Prices $7 Million Public Offering; Shares Fall - marketscreener.com
Medicus Pharma unveils pricing of $7M public offering - Proactive financial news
Medicus Pharma’s (MDCX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Medicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street Zen - Defense World
Medicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment Trials - TipRanks
Medicus Pharma Secures $7M Funding to Advance Revolutionary Skin Cancer Patch Through Phase 2 Trials - Stock Titan
Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering - Newsfile
Medicus Pharma Files For Resale From Time To Time Of Up To 3.7 Mln Common Shares - marketscreener.com
Medicus Pharma begins UAE cancer trial expansion – ICYMI - Proactive financial news
Medicus Pharma’s (MDCX) Buy Rating Reiterated at D. Boral Capital - Defense World
OpenAI’s $6.5B Deal With Jony Ive Hints at a Post-iPhone AI Era - The Globe and Mail
Medicus Pharma receives UAE approval to begin Phase 2 study for non-invasive BCC treatment - Proactive financial news
Small cap wrap: Nextech3D.ai, Medicus Pharma, Synchronoss, ReconAfrica... - Proactive financial news
Medicus Pharma Ltd. Gains UAE Approval for Phase 2 Basal Cell Carcinoma Study - TipRanks
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates Department of Health to Commence Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin - Malay Mail
Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) - Newsfile
New Non-Invasive Skin Cancer Treatment Advances to Phase 2 in UAE After 46% Success Rate - Stock Titan
Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy - Proactive financial news
Major Shareholder Sells Off Huge Chunk of Medicus Pharma Stock! - TipRanks
This Magnificent Stock Is Up 370% From Its 2022 Low -- 2 Reasons to Buy It Now, and 1 Reason to Steer Clear - The Globe and Mail
Chart of the DayJuly Wheat - The Globe and Mail
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money - The Globe and Mail
Is Google Stock Worth Buying In 2025? - The Globe and Mail
Medicus Pharma (NASDAQ:MDCX) Price Target Raised to $27.00 at D. Boral Capital - Defense World
Pre-market Movers: CNSP, XLO, PLRZ, SGMO... - RTTNews
Medicus Pharma Ltd. SEC 10-Q Report - TradingView
Medicus Pharma price target raised to $27 from $14 at D. Boral Capital - TipRanks
Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio - Benzinga
Medicus Pharma secures $15 million funding option - MSN
Medicus Pharma stock target lifted to $27 on Antev acquisition By Investing.com - Investing.com Nigeria
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Medicus Pharma stock target lifted to $27 on Antev acquisition - Investing.com Australia
Certain Common Shares of Medicus Pharma Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2025. - marketscreener.com
Certain Options of Medicus Pharma Ltd. are subject to a Lock-Up Agreement Ending on 12-MAY-2025. - marketscreener.com
Maxim Group Upgrades Medicus Pharma (CVE:MDC) to “Strong-Buy” - Defense World
Medicus Pharma to acquire Antev, advancing opportunity in prostate health solutions - Proactive financial news
Medicus Pharma to acquire Antev for $75M in share exchange transaction - MSN
Medicus Pharma signs letter of intent to buy British biotech company - The Business Journals
Medicus Pharma to acquire Antev in strategic biotech deal By Investing.com - Investing.com South Africa
Medicus Pharma to acquire Antev in strategic biotech deal - Investing.com Australia
Small cap wrap: Medicus Pharma, Arizona Gold & Silver, Plug Power... - Proactive financial news
Market movers: Nvidia, Plug Power, Medicus Pharma... - Proactive financial news
Medicus Pharma Ltd To Acquire Antev Ltd. For $75 Million In A Share Exchange Transaction - marketscreener.com
Medicus Pharma Ltd (MDCX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
0.93%
자본화:
|
볼륨(24시간):